01 Industry overview
The digital pathology industry at a glance
The global digital pathology market is estimated at $1.54 billion in 2026, with adoption expanding as laboratories combine whole-slide imaging, workflow software, and AI-enabled analysis.
- $1.54B[5]
- 2026 market size
- 11.5%[5]
- 2026–2035 CAGR
- 39.92%[4]
- North America share, 2025
- 15%[15]
- U.S. practices using primary diagnosis, 2025
- Market size
- The global digital pathology market was estimated at $1.37 billion in 2025 and $1.54 billion in 2026. Another 2026 estimate placed the 2025 market at $1.53 billion, illustrating the variation caused by differing market definitions and coverage.[5][4]
- Forecast & CAGR
- Global Market Insights forecasts the market to reach $4.1 billion by 2035 at an 11.5% CAGR from 2026 to 2035. Grand View Research projects $3.0 billion by 2033 at an 8.6% CAGR from 2026 to 2033.[5][4]
- Market share & regions
- North America held the largest regional share in 2025, at 39.92% in Grand View Research's estimate and 36.74% in Fortune Business Insights' estimate. Asia-Pacific is identified as the fastest-growing region in both outlooks.[4][6]
- Segmentation
- Software was the largest product segment in 2025, accounting for 42.88% of market revenue in Grand View Research's segmentation. Oncology represented 52.02%, academic research 45.76%, and hospitals 37.15% in their respective application, therapeutic-area, and end-use segments.[4]
- Key players & concentration
- Global Market Insights estimated Danaher as the leading company with more than 15.4% of 2025 market share. Its five leading companies—Danaher, Roche, Fujifilm, Hamamatsu Photonics, and Olympus—collectively accounted for 46.2%.[5]
- Pricing
- The Digital Pathology Association reports that whole-slide scanners typically cost between $50,000 and $300,000, depending on slide capacity and features. Total implementation costs also include storage, data management, software, and operating personnel.[16]
- Trends, drivers & challenges
- Growth is being driven by AI-assisted image analysis, oncology workflows, remote consultation, precision medicine, and demand for faster and more collaborative diagnostics. Adoption remains constrained by scanner and storage costs, high-performance computing requirements, laboratory-information-system integration, validation, and workforce training.[5][15][17]
- Consumer behavior & competition
- The main buyers are hospitals, diagnostic laboratories, academic medical centers, pharmaceutical companies, and research organizations. In the College of American Pathologists' 2025 survey, only 15% of practices reported using whole-slide imaging for primary diagnosis, while academic and reference laboratories were more likely to digitize slides for research, consultation, and tumor boards.[15]
- M&A
- M&A is combining pathology laboratories, scanners, image-management platforms, and AI capabilities. Quest Diagnostics acquired select PathAI Diagnostics assets in 2024 for $100 million, while Tempus announced its acquisition of Paige in 2025 to add AI-enabled digital pathology to its precision-medicine platform.[18][19]
- Regulation
- In the United States, whole-slide imaging systems are regulated medical devices, and the FDA recorded a substantially equivalent 510(k) decision for Roche Digital Pathology Dx on December 17, 2024. Clinical deployment also requires laboratory validation and compliance with applicable quality and diagnostic-use requirements.[20][16]
- Latest news
- Recent industry activity has centered on consolidation and AI integration: Tempus announced the acquisition of Paige in 2025, while 2026 market reporting continues to describe a shift from standalone scanner purchases toward enterprise imaging platforms that combine whole-slide imaging, software, AI, and laboratory integration.[19][5]
02 Ranking
Top 10 Companies in the Digital Pathology Industry
The leading companies in the digital pathology industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Roche stands out for clinical whole-slide scanning and workflow software because it sells VENTANA DP scanners and digital pathology workflow software for clinical diagnosis, while Proscia focuses on digital pathology workflows and AI applications since its Concentriq platform manages digital pathology workflows and AI applications.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in digital pathology workflow
Roche
CH
Ranked #1 · 9.3 · Digital pathology workflow
Why we picked it: Its digital pathology offering combines scanners and workflow software, with a substantially equivalent 510(k) decision recorded in 2024.
Leader in AI-enabled pathology analysis
Proscia
US
Ranked #2 · 9.3 · AI-enabled pathology analysis
Why we picked it: Concentriq is built around end-to-end digital pathology workflow management tied to AI applications.
Leader in enterprise image management
Sectra
SE
Ranked #3 · 9.0 · Enterprise image management
Why we picked it: Its enterprise imaging platform is designed for pathology alongside other specialties in the same imaging environment.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Roche Digital pathology workflow · CH | 9.3 | 9.9 | 8.8 | 9.3 | 9.9 | |
Company snapshot · Roche · Data as of November 20, 2026 Roche sells VENTANA DP scanners and digital pathology workflow software for clinical diagnosis.[21]
| |||||||
| 2 | Proscia AI-enabled pathology analysis · US | 9.3 | 8.5 | 9.9 | 9.9 | 8.9 | |
Company snapshot · Proscia · Data as of November 20, 2026 Proscia's Concentriq platform manages digital pathology workflows and AI applications.[22]
| |||||||
| 3 | Sectra Enterprise image management · SE | 9.0 | 8.5 | 9.2 | 9.4 | 8.9 | |
Company snapshot · Sectra · Data as of November 20, 2026 Sectra's enterprise imaging platform supports pathology alongside radiology and cardiology.[23]
| |||||||
| 4 | PathAI AI-enabled pathology analysis · US | 9.0 | 8.4 | 8.8 | 9.4 | 8.9 | |
Company snapshot · PathAI · Data as of November 20, 2026 PathAI commercializes AISight, a cloud-based digital pathology image management platform.[24]
| |||||||
| 5 | Indica Labs AI-enabled pathology analysis · US | 8.7 | 7.6 | 9.2 | 9.4 | 8.9 | |
Company snapshot · Indica Labs · Data as of November 20, 2026 Indica Labs develops HALO image analysis and clinical digital pathology platforms.[25]
| |||||||
| 6 | Hamamatsu Photonics NanoZoomer whole-slide scanners · JP | 8.5 | 9.0 | 8.2 | 7.9 | 7.6 | |
Company snapshot · Hamamatsu Photonics · Data as of November 20, 2026 Hamamatsu's NanoZoomer portfolio provides whole-slide imaging for clinical and research pathology.[26]
| |||||||
| 7 | Danaher Leica Biosystems pathology workflow and imaging · US | 8.5 | 9.9 | 8.7 | 8.2 | 7.0 | |
Company snapshot · Danaher · Data as of November 20, 2026 Leica Biosystems provides Aperio digital pathology scanners and pathology workflow solutions.[27]
| |||||||
| 8 | Huron Technologies Digital pathology scanners and workflow platform · CA | 8.3 | 7.6 | 8.8 | 9.0 | 7.9 | |
Company snapshot · Huron Technologies · Data as of November 20, 2026 Huron Technologies supplies digital pathology scanners, image management and analysis tools.[28]
| |||||||
| 9 | 3DHISTECH Whole-slide scanners and pathology software · HU | 7.8 | 8.5 | 7.0 | 7.0 | 7.9 | |
Company snapshot · 3DHISTECH · Data as of November 20, 2026 3DHISTECH develops PANNORAMIC scanners and software for clinical and research digital pathology.[29]
| |||||||
| 10 | OptraSCAN Scanners, AI analysis and image management · US | 7.5 | 7.0 | 7.0 | 7.7 | 7.9 | |
Company snapshot · OptraSCAN · Data as of November 20, 2026 OptraSCAN makes whole-slide scanners, AI analysis tools and image management software.[30]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 10 companies in the digital pathology industry. In Digital Pathology Industry Statistics. Gitnux. https://gitnux.org/digital-pathology-industry-statistics/#top-companies
Digital pathology market revenue by region
Asia Pacific holds the largest share at $570.0M.
03 Trends & forecasts
Top 10 Digital Pathology Industry Trends & Forecasts 2027
What is changing in the digital pathology industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Market growth remains double-digit
Medium confidenceGlobal Market Insights estimates the digital pathology market at approximately $1.54 billion in 2026 and forecasts $4.1 billion by 2035, implying an 11.5% CAGR from 2026 to 2035.[5]
Forecast 2027: The market should expand in 2027, but growth will remain uneven as research and consultation deployments convert gradually into routine diagnostic use. A plausible 2027 market range is approximately $1.7–$1.8 billion on the cited 2026 baseline.
02Primary diagnosis adoption accelerates
High confidenceThe College of American Pathologists reported from its 2025 survey that 26% of practices digitized glass slides, but only 15% used whole-slide imaging for primary diagnosis; among practices using WSI, 57% used it for primary diagnosis.[15]
Forecast 2027: Primary-diagnosis use should rise modestly in 2027 as more laboratories complete validation and deploy FDA-cleared systems. Adoption is likely to remain below one-quarter of U.S. practices because infrastructure and workflow barriers will persist.
03Enterprise platforms replace scanner-only buying
High confidenceMarket Global Insights describes a shift from discrete scanner deployments toward enterprise environments combining whole-slide imaging, image management, AI analysis, and laboratory integration. The Pathologist reports that laboratories historically bought scanners first and added image-management and AI tools as slide volumes increased.[5][31]
Forecast 2027: In 2027, purchasing should increasingly favor integrated platforms, subscription software, and implementation services rather than standalone scanners. Vendors able to connect scanning, LIS workflows, storage, and AI will capture more value per deployment.
04AI moves toward clinical workflows
High confidenceTempus acquired Paige in August 2025 for $81.25 million, adding digital-pathology AI and almost 7 million clinically annotated digitized slides. Paige also had an FDA-cleared pathology AI application, according to Tempus.[19]
Forecast 2027: In 2027, AI deployment should move beyond pilot demonstrations toward narrower, workflow-embedded applications such as cancer detection, biomarker assessment, quality control, and prioritization. Human pathologist review will remain central for most primary-diagnosis use cases.
05Oncology remains the leading use case
High confidenceTempus characterized Paige's digital-pathology platform as relevant to cancer detection and precision medicine, while Quest's 2024 transaction with PathAI was explicitly designed to accelerate AI and digital pathology adoption in cancer diagnosis.[19][32]
Forecast 2027: Cancer pathology should continue to account for the largest share of clinical digital-pathology activity in 2027. Breast, prostate, lung, and hematopathology workflows are likely to attract the most AI commercialization because of high case volumes and strong links to treatment decisions.
06Large-capacity scanning gains ground
High confidenceRoche's VENTANA DP 600, cleared as part of its Digital Pathology Dx system, can process 240 slides and was positioned for high-volume clinical diagnosis. The clearance expanded the system beyond the earlier DP 200 scanner.[21]
Forecast 2027: High-throughput scanners should gain share in 2027 as laboratories consolidate volume and seek lower labor cost per slide. Smaller scanners will remain relevant for low-volume hospitals, specialty practices, and research settings.
07Scanner prices remain a major barrier
High confidenceThe Digital Pathology Association says whole-slide scanners typically cost between $50,000 and $300,000, excluding broader spending on storage, data management, software, and operating personnel.[16]
Forecast 2027: Scanner prices should remain broadly stable in nominal terms through 2027, while total cost of ownership becomes more important in purchasing decisions. Vendors are likely to use leasing, cloud services, and bundled contracts to reduce upfront capital requirements.
08Interoperability becomes procurement-critical
High confidenceThe 2026 Journal of Pathology Informatics review says proprietary whole-slide formats continue to limit interoperability and identifies DICOM adoption as a route toward vendor-neutral exchange. ISO 12052:2026 explicitly covers medical-image exchange and applies to pathology as well as radiology and other imaging disciplines.[33][34]
Forecast 2027: By 2027, DICOM support and documented conformance should become stronger differentiators in enterprise procurements. Interoperability will improve, but legacy systems and vendor-specific extensions will prevent a fully frictionless market.
09Regulatory clearances broaden clinical supply
High confidenceThe FDA recorded a substantially equivalent 510(k) decision for Roche Digital Pathology Dx on December 17, 2024. Roche's system includes the VENTANA DP 200 and, after an additional clearance, the DP 600 for aiding clinical diagnosis.[20][21]
Forecast 2027: The 2027 product pipeline should contain more cleared scanners, workflow components, and narrowly defined AI applications. Regulatory evidence and laboratory validation will increasingly shape commercial launch timing and purchasing decisions.
10Consolidation links labs and AI
High confidenceQuest Diagnostics agreed to acquire select PathAI Diagnostics assets in 2024, combining Quest's laboratory scale with PathAI's AI and digital-pathology capabilities. Tempus subsequently agreed to acquire Paige for $81.25 million in 2025.[32][19]
Forecast 2027: M&A should continue in 2027, particularly where diagnostic laboratories can supply clinical volume and AI companies can supply algorithms, data, and software. The market will likely become more concentrated around vendors with complete clinical and computational offerings.
04 Statistics
Technology & AI
AI adoption concentrates on image-analysis applications, with 87% of AI adopters using them. Regulatory eligibility also shows a measured pipeline: 26 AI products from 15 companies.
AI features and adoption in the digital pathology industry
- 87% of AI adopters in the digital pathology survey were using image-analysis applications, compared with process automation as another reported AI use.[1]
- 26 digital pathology AI products from 15 companies had regulatory approval for placement on the EEA or GB market under the study’s eligibility criteria.[2]
- 82% of life-sciences organizations using digital pathology had implemented AI applications in the 2023 survey of 40 executives from major pharmaceutical companies and CROs.[1]
05 Statistics
Market Intelligence
Market sizing differs by definition, including $1.37 billion in 2025 in one estimate and $1.53 billion in another 2025 estimate. In 2026, the market is estimated at $1.54 billion.
Market size and revenue in the digital pathology industry
- US$226 million was the estimated 2025 global digital pathology software and platform market, covering web-based and desktop software for hospitals, diagnostic centres, laboratories and research institutes.[3]
- US$1.5 billion was the 2025 global digital pathology market size, covering hardware, software and storage systems; software represented 42.88% of revenue.[4]
- US$1.37 billion was the 2025 global digital pathology market size, covering products, software, scanners, image-management systems and AI-based image analysis.[5]
Growth forecasts for the digital pathology industry
- The global digital pathology market is projected to reach US$5.75 billion by 2034, at an 18.56% CAGR from 2026 to 2034; the scope includes hardware, software and storage systems.[6]
- The global digital pathology market is projected to reach US$3.0 billion by 2033, growing at an 8.6% CAGR from 2026 to 2033; the scope includes hardware, software and storage systems.[4]
- The global digital pathology market is projected to reach US$4.1 billion by 2035, growing at an 11.5% CAGR from 2026 to 2035; the scope includes scanners, software, platforms and related systems.[5]
Product counts and provider structure in the digital pathology industry
- 115 products performed image analysis on H&E-stained histological tissue images in the reviewed digital pathology AI product population.[2]
- 60 companies were identified as developing digital pathology AI-based image-analysis software in a review of publicly available products.[2]
- 12 leading companies were profiled in a global digital pathology software and platform market study covering hospitals, diagnostic centres, laboratories and research institutes.[3]
06 Statistics
Customers & Revenue
Clinical primary diagnosis uptake stays limited: only 15% of U.S. practices reported using whole-slide imaging for primary diagnosis in 2025. Survey results for life sciences also show wide use: 70% in February 2023.
Buyer penetration in the digital pathology industry
- Fewer than 15% of U.S. healthcare organizations were at any stage of digital-pathology deployment in 2026; the denominator was U.S. healthcare organizations.[7]
- 70% of surveyed life-sciences organizations currently used digital pathology in February 2023; the denominator was 40 executives from pharmaceutical companies and CROs in the United States, Europe, Middle East and Africa.[1]
- Fewer than 10% of U.S. organizations had adopted digital pathology for clinical use in 2023; the denominator was U.S. healthcare organizations.[8]
07 Statistics
Pricing & Packaging
Subscription pricing shows low-cost entry points alongside enterprise scale requirements, with SlideScope Plus at $50 per month observed in November 2026 and other tiers sold by case volume.
Price levels in the digital pathology industry
- $50 per month was SlideScope Plus’s published subscription price, observed in November 2026; the product was sold globally in U.S. dollars.[9]
- ฿39,900 per month was the published PATHOLOGY+ Lab + AI plan price for up to 30 users and 2,000 new cases monthly, observed in November 2026; the service was hosted and sold in Thailand.[10]
- ฿14,900 per month was the published PATHOLOGY+ Lab plan price for up to 10 users and 500 new cases monthly, observed in November 2026; the service was hosted and sold in Thailand.[10]
- $35 per month was SlideScope Individual’s published subscription price for opening users’ own digital-pathology images, observed in November 2026; the product was sold globally in U.S. dollars.[9]
08 Statistics
Security & Compliance
EU AI Act timing is specified for digital pathology AI within high-risk rules, with an application date of 2 August 2026 for most rules and 2 August 2028 for embedded high-risk systems.
Regulatory obligations in the digital pathology industry
- 2 December 2027 is the application date for high-risk AI systems under Annex III of the EU AI Act in the EU, covering applicable stand-alone clinical AI software, including relevant digital-pathology applications.[11]
- 2 August 2028 is the application date for high-risk AI systems embedded in regulated products under Annex I of the EU AI Act, including applicable AI-enabled medical-device software used in digital pathology.[12]
- 2 August 2026 is the application date for most EU AI Act rules, including transparency requirements, for applicable AI software in the EU; digital-pathology AI systems are covered when they fall within the regulated-product framework.[11]
09 Statistics
Sustainability
Carbon accounting is quantified for digital pathology compute workloads, including 100.56 metric tonnes CO2-equivalent per year for seven deep-learning models in Aachen, Germany.
Energy use, emissions and disclosure in the digital pathology industry
- 100.56 metric tonnes of CO2-equivalent emissions per year were modelled for seven deep-learning models applied to the same prostate and breast digital-pathology slide workload in Aachen, Germany.[13]
- 1,103–2,923 tonnes of CO2-equivalent emissions were estimated for full digitalisation of surgical pathology in France, depending on external versus local storage and three-month versus one-year retention.[14]
- 7.65 metric tonnes of CO2-equivalent emissions per year were modelled for one deep-learning model applied to all prostate and breast whole-slide images in digital pathology in Aachen, Germany, in the study scenario.[13]
Key questions about the digital pathology industry
What is the 2026 market size for digital pathology?
How fast is the digital pathology market growing over the next decade?
Which companies lead the digital pathology industry?
What technology shift is most visible in digital pathology adoption?
How is the market structured across products and applications?
What constrains adoption and deployment in clinical settings?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). Digital Pathology Industry Statistics. Gitnux. https://gitnux.org/digital-pathology-industry-statistics
Samuel Norberg. "Digital Pathology Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/digital-pathology-industry-statistics.
Samuel Norberg. 2026. "Digital Pathology Industry Statistics." Gitnux. https://gitnux.org/digital-pathology-industry-statistics.
Sources & references
34 sources cited across this report
- 242781507.fs1.hubspotusercontent-na2.net
nature.com
marketresearchreports.com
grandviewresearch.com
gminsights.com
fortunebusinessinsights.com
engage.klasresearch.com
klasresearch.com
- slidescope.science
- pathology.plus
ai-act-service-desk.ec.europa.eu
digital-strategy.ec.europa.eu
pmc.ncbi.nlm.nih.gov
- pathologyjournal.rcpa.edu.au
cap.org
digitalpathologyassociation.org
pubmed.ncbi.nlm.nih.gov
sec.gov
- investors.tempus.com
accessdata.fda.gov
diagnostics.roche.com
proscia.com
investor.sectra.com
pathai.com
indicalab.com
nanozoomer.hamamatsu.com
danaher.com
- hurontechnologies.com
3dhistech.com
- optrascan.com
- thepathologist.com
newsroom.questdiagnostics.com
sciencedirect.com
iso.org